Tivozanib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tivozanib: From Renal Cell Carcinoma to Endocervical Carcinoma
Note on data completeness: This Evidence Pack does not populate
original_indicationsororiginal_moa(both flagged as data gaps DG001/DG002, with DG001 rated Blocking). The original indication below is based on general pharmacological knowledge of tivozanib (a marketed VEGFR TKI for renal cell carcinoma) and requires confirmation against the TFDA/Fimea package insert before this report can be used for decision-making.
One-Sentence Summary
Tivozanib is a highly selective VEGFR-1/2/3 tyrosine kinase inhibitor originally developed for renal cell carcinoma. The TxGNN model predicts it may be effective for Endocervical Carcinoma, but currently 0 clinical trials and 0 publications support this specific direction — the signal is a pure graph-based prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Renal cell carcinoma (general knowledge; not present in evidence pack — data gap) |
| Predicted New Indication | Endocervical carcinoma |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L5 |
| Finland Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed original mechanism-of-action data is marked as a data gap in this evidence pack. However, according to the repurposing rationale attached to the prediction, tivozanib is a highly selective VEGFR-1/2/3 tyrosine kinase inhibitor that suppresses tumor angiogenesis.
Endocervical carcinoma, like renal cell carcinoma, can be angiogenesis-dependent, and other anti-angiogenic agents (e.g., bevacizumab) are already approved for advanced cervical cancer. This gives the prediction a plausible mechanistic analogy at the drug-class level.
That said, the link is derived purely from TxGNN's knowledge-graph similarity — there is no tivozanib-specific study, case report, or preclinical data in endocervical carcinoma to confirm the mechanism actually translates to clinical benefit in this tumor type.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Finland Market Information
Tivozanib currently has no marketing authorization in Finland (0 licenses on record); no product table is available.
Cytotoxicity
Tivozanib is an antineoplastic agent (VEGFR tyrosine kinase inhibitor).
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (VEGFR-1/2/3 tyrosine kinase inhibitor / anti-angiogenic agent) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on a TxGNN graph score (L5, decision stage S0) with zero supporting clinical trials or literature across all 10 candidate gynecological indications queried, and the drug's own TFDA/Fimea label data is unresolved (a Blocking-severity gap).
To proceed, the following is needed:
- TFDA/Fimea package insert (warnings, contraindications, DDI) — currently Blocking gap DG001
- Confirmed original MOA and approved indication from DrugBank/regulatory source — DG002
- Preclinical or case-level evidence of VEGFR pathway relevance specifically in endocervical carcinoma before any trial-stage investment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.